Diabetes treatment start-up funding round takes total capital to £3.6m

UK-based digital health start-up Quin has just closed its latest fundraising round, placing its total capital raised to date at £3.6 million.

Quin is female-founded and led by Cyndi Williams. It provides personalised, continuous, data-led support for insulin dosing decisions, based on behavioural and physiological factors. It has had over 10,000 downloads in the UK & Ireland.

People with type 1 diabetes make approximately 180 decisions a day, weighing a variety of factors that affect their health. This number of decisions made without support can cause significant stress and even difficulties with mental health. A report by the All-Party Parliamentary Group for Diabetes in 2018 found that 42% of people with type 1 diabetes experience elevated distress. Results from beta tests of the app show 84% of users experienced better health outcomes or quality of life, or both.

Quin CEO and co-founder, Cyndi Williams said: “I am so proud of the progress we have made at Quin, and grateful to have such a brilliant team and network of investors backing us. It is quite something, as a UK health tech start-up to raise this kind of funding working remotely during a pandemic. This shows the conviction investors have – as we do at Quin – in the potential of personalised digital health apps to change the lives of people with long term health conditions. We carry around so much data in our pockets that could be put to much better use in improving health outcomes for everyone. We have a lot to do over the next 12 months, and these new funds give us the freedom to make it happen.”

Quin is available on the App Store for iPhone users with type 1 diabetes to download. The Quin app is most suitable for people who use insulin pens and a continuous glucose monitor (CGM) but can be used by pen users who don’t have a CGM, making it a solution for most people with type 1 diabetes. The app is currently limited to the UK and Ireland App Stores, but the company has plans for global availability this year.

The original article can be found at: Med-Tech Innovation News